STRO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
STRO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-12-14), the Trailing Annual Dividend Yield of Sutro Biopharma is 0.00%.
The historical rank and industry rank for Sutro Biopharma's Dividend Yield % or its related term are showing as below:
Sutro Biopharma's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00.
As of today (2024-12-14), the Forward Dividend Yield % of Sutro Biopharma is 0.00%.
Sutro Biopharma's Dividends per Share for the three months ended in Sep. 2024 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
The historical data trend for Sutro Biopharma's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
Sutro Biopharma Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Sutro Biopharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Sutro Biopharma (NAS:STRO) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Sutro Biopharma's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Nicki Vasquez | officer: Chief Port. Strat & Alnce Ofcr | C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080 |
Hans-peter Gerber | officer: Chief Scientific Officer | C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Brunilda Shtylla | officer: Chief Business Officer | C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
Venkatesh Srinivasan | officer: Chief Tech Op Officer | C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
Anne Elizabeth Borgman | officer: Chief Medical Officer | 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705 |
William J Newell | director, officer: CEO & President | 887 GREAT NORTHERN WAY, VANCOUVER A1 V5T 4T5 |
Heidi Hunter | director | C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080 |
Jane Chung | officer: Chief Commercial Officer | C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080 |
Trevor Hallam | officer: Chief Science Officer | PALATIN TECHNOLOGIES, INC., 4C CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Jon Marc Wigginton | director | 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
John Gordon Freund | director, 10 percent owner | 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301 |
Arturo Md Molina | officer: Chief Medical Officer | 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024 |
Linda A Fitzpatrick | officer: Chief People & Comm. Officer | NUVELO, INC., 675 ALMANOR AVENUE, SUNNYVALE CA 94085 |
James P Panek | director | C/O VAXGEN INC, 1000 MARINA BLVD. #200, BRISBANE CA 94005 |
Matsui Connie | director | 3030 CALLAN RD, SAN DIEGO CA 92121 |
From GuruFocus
By GuruFocus Research • 02-09-2024
By Marketwired • 09-11-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 08-22-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GlobeNewswire • 09-14-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 08-13-2024
By GuruFocus Research • 02-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.